DiscGenics announced allowance of 9 additional patents, including two in the U.S. and seven in EU markets. The company is developing spinal stem cell therapeutics.
This expands the company’s global intellectual property portfolio to 24 issued patents covering the proprietary culture process and novel Discogenic Cell technology that is the therapeutic agent within its first product, Injectable Discogenic Cell Therapy (IDCT).
The company is completing preclinical development and seeks to initiate a human clinical trial during 2017, pending regulatory approvals. Its first patent in the U.S. was issued in 2012, addressing compositions of adult disc stem cells and methods for treatment of degenerative disc disease.
DiscGenics announced allowance of 9 additional patents, including two in the U.S. and seven in EU markets. The company is developing spinal stem cell therapeutics.
This expands the company's global intellectual property portfolio to 24 issued patents covering the proprietary culture process and novel Discogenic Cell technology that is the...
DiscGenics announced allowance of 9 additional patents, including two in the U.S. and seven in EU markets. The company is developing spinal stem cell therapeutics.
This expands the company’s global intellectual property portfolio to 24 issued patents covering the proprietary culture process and novel Discogenic Cell technology that is the therapeutic agent within its first product, Injectable Discogenic Cell Therapy (IDCT).
The company is completing preclinical development and seeks to initiate a human clinical trial during 2017, pending regulatory approvals. Its first patent in the U.S. was issued in 2012, addressing compositions of adult disc stem cells and methods for treatment of degenerative disc disease.
Copy to clipboard 
